- Post–T-DXd Sacituzumab Govitecan Plus Trastuzumab Yields Low ORR in HER2+ Metastatic Breast CancerSacituzumab govitecan plus trastuzumab following T-DXd did not meet the primary end point of the SATEEN trial in HER2+ metastatic breast cancer.onclive · 2mo ago↗ source
- Dr Sznol on the Nuances of Recommending Neoadjuvant Therapy in Metastatic MelanomaMario Sznol, MD, discusses current guidance around the use of neoadjuvant therapy in advanced melanoma.onclive · 2mo ago↗ source
- Biomarker-Directed Therapies Move the GI Oncology Paradigm Beyond a One-Size-Fits-All Approach: With Michael J. Pishvaian, MD, PhDMichael J. Pishvaian, MD, PhD discusses how biomarker-directed strategies, including HER2, CLDN18.2, and KRAS inhibition, are transforming GI cancer care.